An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime), and Magellan Rx Management, (Magellan Rx), a Prime Therapeutics company, shows that 68 percent of individuals who newly started glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss were no longer taking the drug after one year
For several years, many peptide and chemical suppliers sold GLP-1 compounds such as semaglutide and tirzepatide using labels like Research Use Only (RUO) or Not for Human Consumption . These disclaimers were intended to signal that the products were not meant for patients or consumers
The active peptide is combined with a simple, transparent ingredient list including D-ribose, purified water, citric acid, and certified organic peppermint essential oil to support ease of use and palatability
How the two obesity compounds actually compare in 2026
This is supported by the ADA Standards of Care in Diabetes